KCNC3: A Potential Drug Target and Biomarker for Shaw-Related Voltage-Gated Potassium Channels

Target Name: KCNC3

NCBI ID: G3748

KCNC3

Other Name(s): Shaw-related voltage-gated potassium channel protein 3 | KV3.3 | voltage-gated potassium channel protein KV3.3 | KCNC3_HUMAN | voltage-gated potassium channel subunit Kv3.3 | Voltage-gated potassium channel subunit Kv3.3 | Potassium voltage-gated channel subfamily C member 3 (isoform 1) | KCNC3 variant 1 | Potassium voltage-gated channel subfamily C member 3 | Potassium voltage-gated channel subfamily C member 3 isoform 2 | KSHIIID | potassium channel, voltage gated Shaw related subfamily C, member 3 | Voltage-gated potassium channel protein KV3.3 | SCA13 | Potassium voltage-gated channel subfamily C member 3, transcript variant 3 | Potassium voltage-gated channel subfamily C member 3, transcript variant 1 | KCNC3 variant 3 | Potassium channel, voltage gated Shaw related subfamily C, member 3 | potassium voltage-gated channel, Shaw-related subfamily, member 3 | potassium voltage-gated channel subfamily C member 3 | Kv3.3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3

KCNC3: A Potential Drug Target and Biomarker for Shaw-Related Voltage-Gated Potassium Channels

Abstract:

Shaw-related voltage-gated potassium channels (KCNCs) are a family of ion channels that play a crucial role in various physiological processes, including muscle contractions and intracellular signaling. The third member of this family, KCNC3, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. This article summarizes the current understanding of KCNC3, its functions, and potential therapeutic applications.

Introduction:

KCNCs are a family of voltage-gated potassium channels that are characterized by their unique subunit structure, which consists of a catalytic alpha-helices, a transmembrane segment, and a carboxy-terminal region. These channels are involved in various physiological processes, including muscle contractions, neural signaling, and intracellular signaling. The third member of this family, KCNC3, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders.

Cells and Functions:

KCNC3 is a member of the voltage-gated potassium channel subfamily I (SCN4A subfamily), which is responsible for generating action potentials in neurons and other excitable cells. These channels are involved in the regulation of various physiological processes, including muscle contractions, neural signaling, and intracellular signaling.

KCNC3 is expressed in a variety of tissues, including neurons, muscle cells, and pancreatic beta cells. It is highly selective for certain concentrations of K+ ions, allowing it to play a crucial role in the regulation of these processes. Additionally, KCNC3 is involved in the regulation of ion channels in various tissues, including the heart, gut, and respiratory tract.

Despite its importance, KCNC3 is not well understood, and research into its functions and potential therapeutic applications is in its infancy. recent studies have identified potential targets for KCNC3, including several kinases, which are known to regulate the activity of these channels. Additionally, several studies have identified potential biomarkers for KCNC3-related disorders, including altered brain volume and reduced neuronal density in individuals with certain psychiatric disorders.

The Potential Therapeutic Applications of KCNC3:

KCNC3 is a promising drug target for a variety of neurological and psychiatric disorders. Its functions in the regulation of muscle contractions, neural signaling, and intracellular signaling make it a potential target for disorders such as myopathies (dystrophies), neurodegenerative diseases, and psychiatric disorders.

1. Myopathies:

Myopathies are a group of genetic disorders characterized by muscle weakness and dysfunction. Many myopathies are caused by mutations in the genes responsible for the construction of the affected ion channels. KCNC3 mutations have been identified in individuals with various myopathies, including dystrophies. These mutations have been shown to alter the activity of these channels and contribute to the pathophysiology of these disorders.

1. Neurodegenerative Diseases:

Neurodegenerative diseases are a group of disorders characterized by the progressive loss of neuronal cells. These disorders include Alzheimer's disease, Parkinson's disease, and Huntington's disease. KCNC3 mutations have been identified in individuals with these disorders, and these mutations have been shown to alter the activity of these channels and contribute to the pathophysiology of these disorders.

1. Psychiatric Disorders:

Psychiatric disorders, including depression and anxiety, are a common cause of morbidity and mortality. KCNC3 mutations have been identified in individuals with various psychiatric disorders, and these mutations have been shown to alter the activity of these channels and contribute to the pathophysiology of these disorders.

The Identification of Potential KCNC3-Related Biomarkers:

The identification of potential biomarkers for KCNC3-related disorders is an important step in the development of new therapeutic approaches. Several studies have identified altered brain volume and reduced neuronal density in individuals with certain psychiatric disorders, which may be indicative of altered channel activity. Additionally, some studies have shown that individuals with certain psychiatric disorders have reduced levels of certain compounds, such as serotonin and dopamine, which are involved in neurotransmission.

Conclusion:

In conclusion, KCNC3 is a promising drug target and biomarker for various neurological and psychiatric disorders. Its functions in the regulation of muscle contractions, neural signaling, and intracellular signaling make it a potential target for disorders such as myopathies, neurodegenerative diseases, and psychiatric disorders. The identification of potential biomarkers for these disorders is an important step in the development of new therapeutic approaches. Further research is needed to fully understand the functions of KCNC3 and its potential as a drug target and biomarker.

Protein Name: Potassium Voltage-gated Channel Subfamily C Member 3

Functions: Voltage-gated potassium channel that plays an important role in the rapid repolarization of fast-firing brain neurons. The channel opens in response to the voltage difference across the membrane, forming a potassium-selective channel through which potassium ions pass in accordance with their electrochemical gradient. The channel displays rapid activation and inactivation kinetics (PubMed:10712820, PubMed:26997484, PubMed:22289912, PubMed:23734863, PubMed:16501573, PubMed:19953606, PubMed:21479265, PubMed:25756792). It plays a role in the regulation of the frequency, shape and duration of action potentials in Purkinje cells. Required for normal survival of cerebellar neurons, probably via its role in regulating the duration and frequency of action potentials that in turn regulate the activity of voltage-gated Ca(2+) channels and cellular Ca(2+) homeostasis (By similarity). Required for normal motor function (PubMed:23734863, PubMed:16501573, PubMed:19953606, PubMed:21479265, PubMed:25756792). Plays a role in the reorganization of the cortical actin cytoskeleton and the formation of actin veil structures in neuronal growth cones via its interaction with HAX1 and the Arp2/3 complex (PubMed:26997484)

The "KCNC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets